Hims & Hers Health, Inc. (NYSE:HIMS - Get Free Report) insider Soleil Boughton sold 9,463 shares of the firm's stock in a transaction dated Monday, April 20th. The stock was sold at an average price of $30.00, for a total value of $283,890.00. Following the completion of the transaction, the insider owned 299,368 shares of the company's stock, valued at approximately $8,981,040. The trade was a 3.06% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Soleil Boughton also recently made the following trade(s):
- On Tuesday, March 17th, Soleil Boughton sold 4,812 shares of Hims & Hers Health stock. The stock was sold at an average price of $24.69, for a total value of $118,808.28.
Hims & Hers Health Trading Down 2.7%
Shares of NYSE:HIMS opened at $28.95 on Thursday. Hims & Hers Health, Inc. has a 52-week low of $13.74 and a 52-week high of $70.43. The stock has a market cap of $6.60 billion, a price-to-earnings ratio of 56.77, a PEG ratio of 2.83 and a beta of 2.32. The company has a quick ratio of 1.70, a current ratio of 1.90 and a debt-to-equity ratio of 1.80. The business has a 50-day moving average price of $20.45 and a 200-day moving average price of $31.74.
Hims & Hers Health (NYSE:HIMS - Get Free Report) last announced its quarterly earnings data on Monday, February 23rd. The company reported $0.08 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.02 by $0.06. Hims & Hers Health had a return on equity of 22.48% and a net margin of 5.47%.The firm had revenue of $617.82 million during the quarter, compared to analysts' expectations of $619.48 million. During the same period last year, the business posted $0.11 earnings per share. The company's revenue for the quarter was up 28.4% compared to the same quarter last year. Equities analysts predict that Hims & Hers Health, Inc. will post 0.61 EPS for the current year.
More Hims & Hers Health News
Here are the key news stories impacting Hims & Hers Health this week:
- Positive Sentiment: Pipeline & partner speculation — Momentum behind HIMS has been driven by reports of FDA peptide news and a potential partnership with Novo Nordisk, which traders say helped push the stock higher as investors price in new commercial opportunities. Read More.
- Positive Sentiment: Product expansion — HIMS announced it will offer perimenopause/menopause treatment options (including estrogen patch access) on its telehealth platform, expanding addressable market and recurring-care use cases. This is a direct revenue opportunity and supports the company’s DTC care‑platform narrative. Read More.
- Neutral Sentiment: Sector/flow dynamics — Broader small‑cap biotech and telehealth sector enthusiasm (positive clinical results at peers, flow into health names) has amplified HIMS moves even where company‑specific catalysts are limited. That can accelerate swings up or down ahead of earnings. Read More.
- Neutral Sentiment: Analyst & institutional backdrop — Coverage is mixed: consensus is a “Hold” with a mid‑$30s/low‑$20s range of targets and heavy institutional ownership (~63%). Upgrades/target changes have helped sentiment but don’t fully resolve execution risk. Read More.
- Negative Sentiment: Insider selling — CFO Oluyemi Okupe and other insiders have sold sizable blocks recently under pre‑arranged Rule 10b5‑1 plans (April filings). While 10b5‑1 execution mutes signaling, the volume and timing can weigh on near‑term sentiment. Read More. Read More.
- Negative Sentiment: Competitive threat — Amazon’s launch of a GLP‑1 weight‑loss program highlights new, deep-pocketed competition in a key monetizable category for HIMS (weight‑loss/medication access + ongoing care). That announcement pressured the stock amid concerns about margin compression and customer share loss. Read More.
Wall Street Analysts Forecast Growth
Several research analysts recently weighed in on HIMS shares. Needham & Company LLC upgraded Hims & Hers Health from a "hold" rating to a "buy" rating and set a $30.00 price target for the company in a research report on Monday, March 9th. Weiss Ratings reiterated a "hold (c)" rating on shares of Hims & Hers Health in a research report on Friday, March 27th. Barclays lifted their price target on Hims & Hers Health from $25.00 to $29.00 and gave the company an "overweight" rating in a research report on Wednesday, March 11th. Zacks Research upgraded Hims & Hers Health from a "strong sell" rating to a "hold" rating in a research report on Wednesday, February 25th. Finally, Citigroup upgraded Hims & Hers Health from a "sell" rating to a "neutral" rating and lifted their price target for the company from $13.25 to $24.00 in a research report on Tuesday, March 10th. Three analysts have rated the stock with a Buy rating, thirteen have assigned a Hold rating and one has given a Sell rating to the company's stock. According to data from MarketBeat, Hims & Hers Health presently has a consensus rating of "Hold" and a consensus price target of $31.86.
Read Our Latest Stock Report on Hims & Hers Health
Institutional Trading of Hims & Hers Health
Several institutional investors have recently bought and sold shares of HIMS. Quent Capital LLC acquired a new stake in Hims & Hers Health in the third quarter valued at approximately $28,000. Flagship Harbor Advisors LLC acquired a new stake in Hims & Hers Health in the fourth quarter valued at approximately $28,000. Binnacle Investments Inc acquired a new stake in Hims & Hers Health in the third quarter valued at approximately $28,000. Bogart Wealth LLC grew its holdings in Hims & Hers Health by 235.8% in the fourth quarter. Bogart Wealth LLC now owns 900 shares of the company's stock valued at $29,000 after purchasing an additional 632 shares during the period. Finally, Geneos Wealth Management Inc. acquired a new stake in shares of Hims & Hers Health in the first quarter worth approximately $30,000. 63.52% of the stock is owned by institutional investors and hedge funds.
Hims & Hers Health Company Profile
(
Get Free Report)
Hims & Hers Health, Inc is a telehealth platform providing direct-to-consumer personal care products and virtual medical services in the United States. Operating under the Hims & Hers brand, the company offers an integrated digital experience that connects users with licensed healthcare providers, enabling online consultations and prescriptions for a range of conditions. Its telemedicine infrastructure supports both prescription medications and over-the-counter products, with home delivery to patients' doorsteps.
The company's product portfolio addresses key areas of men's and women's health, including hair loss treatments, sexual wellness therapies, skincare regimens and mental health support.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
